Regulation of Bottled Water August 28, 2010
Which statement from the paragraph on page 4
identifies a weakness in the regulation of drinking
water?
Regulation of Bottled Water Action Committee
Statement of William Diaz, Director,
Environmental Resources Research Group
Tap water suppliers are required by the
Environmental Protection Agency (EPA) to provide
annual consumer confidence reports.
Ms. Chairwoman and Members of the
Committee:
Companies that make bottled water must list basic
ingredients and nutritional information on their
labels.
Thank you for inviting me here today. I am
pleased to contribute to the discussion on the
quality and safety of bottled water. Today we
are releasing our study on bottled water in
the United States. The study shows that over
10 years, Americans' consumption of bottled
water has doubled. In 2008 alone, Americans
drank 8.6 billion gallons of bottled water. This
Companies are not required to disclose the source
of the water, how it is treated, or how it is tested for
contaminants.
1
2 3
4
5
6
Consumer confidence reports summarize the
quality of local tap water and reveal information
about any known contaminants.

6  then the  lord  said to cain, “why are you angry?   why is your face downcast?   7  if you do what is right, will you not be accepted? but if you do not do what is right, sin is crouching at your door;   it desires to have you, but you must rule over it.”

8  now cain said to his brother abel, “let’s go out to the field.”  while they were in the field, cain attacked his brother abel and killed him.

    resources

    news

workshop on enhancing communication around influenza vaccination (weeciv)

centers for disease control and prevention, atlanta, usa,

11-13 june 2013

context

investment in early intervention health care is a proven strategy to decrease high costs burdening the public and government sectors. by strengthening preparedness capacity and supporting low-cost preventative services, mortality rates and the health of populations can be significantly improved. over the past 6 years, considerable investments have been made to establish and expand influenza vaccine manufacturing capacity in developing countries. these investments have improved preparedness for seasonal and pandemic influenza, and have indirectly improved health systems, surveillance, detection, and response activities by leveraging additional support and building capacity within these countries and regions. to fully maximize investments and to ensure sustainability of influenza vaccine manufacturing in developing countries, there is a need to increase national and regional uptake of vaccination.

the percentage of who member states incorporating seasonal influenza vaccination into national immunization programs remains low with significant regional variations. high vaccine and service costs, competing health priorities, difficulties in measuring vaccine efficacy and cost–effectiveness, and adverse public opinion regarding vaccination all influence the policy decisions affecting national immunization programs.

effectively communicating the benefit of influenza vaccination is an essential component to increase the vaccine uptake and inclusion into national influenza immunization programmes. firstly, these benefits need to be understood by the key players that promote vaccination at national level (health promotion departments and healthcare workers). health care workers are increasingly important in influencing vaccination choices, and new appro